U.S. Patient and Trademark Office, U.S. DEPARTMEN
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid Office.

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
( Not for submission under 37 CFR 1.99)

Application Number		10561823			
Filing Date		2005-12-19			
First Named Inventor Joerg		en Hansen			
Art Unit		1632			
Examiner Name					
Attorney Docket Number		14455,880US01			

					U.S.	PATENTS			Remove		
Examiner Initial*	Cite No	Patent Number	tent Number Kind Code1 Issue Date Name of Patentee or Applic of cited Document			Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear					
	1										
If you wisl	h to a	i dd additional U.S. Patei	nt citatio	n inform	ation pl	l lease click the	Add button.		Add		
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publica Date	tion	Name of Patentee or Applicant Re		Releva		Lines where ges or Relev	
	1	20060275877	A1	2006-12	:-07	Joergen Hans	en, et al.				
If you wisi	h to a	dd additional U.S. Publi						d button	Add		
				FOREIG	JN PAI	ENT DOCUM	ENIS	-		1	
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>		Kind Code <sup>4</sup>	Publication Date	Name of Patente Applicant of cited Document	or	vhere Rel	or Relevant	т.
	1	WO 03/048375	wo		A1	2003-06-12	Biotica Technology Limited				
	2	WO 01/79520	wo		A1	2001-10-25	Biotica Technology Limited				Г
	3	WO 01/40491	wo		A2	2001-06-07	Luminis Pty, Ltd.; F Veterinary and Ag.				

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10561823		
Filing Date		2005-12-19		
First Named Inventor Joerg		en Hansen		
Art Unit		1632		
Examiner Name				
Attender Dealest Number		14455 990 ISO1		

	4	WO 03/066836	wo	A2	2003-08-14	E. I. DuPont De Nemours and Co.		
If you wis	h to a	dd additional Foreign Pa	stent Document	citation	information pl	lease click the Add butto	n Add	_
			NON-PATE	NT LITI	ERATURE DO	CUMENTS	Remove	
Examiner Initials*	Cite No							
	OUROS, LM, et al. "Two glocop/manderses and a glocodese en movied in cleandorspin modification during to biosynthese by strengtomps emblections." AMICECULAR MEDICINECTOR (MICHOLOGY OF MICHOLOGY OF MI							
	RATY, K. et al.: 'A gene cluster from streptomyces galifeeus involved in glycosylation of aciarubicin' MOLECULAR AND GENERAL GENETICS, vol. 264, no. 1-2, September 2000 (2000-09), pages 164-172, XP002304279; ISSN: 0026-8025, abstract.							
	SANCHEZ, CESAR, et al.: "The biosynthetic gene cluster for the arithmor rebecoamycin: Characterization and generation of indiscontance demantative ("CEMBSTRY AND BIOLOGY (LONDON), vs. 9, no. 4, April 2002 (2002-04), pages 16-251, XVPASCH, 2500; cells (pages 1.3) 4							
	ARANA, FRANCISCA E.: "Action of a beta-glacosidase in the curing of Vanilla" FOOD RESEARCH, ISSN: 0096-974X, 4 vol. 3, 1943, pages 437-351, XP000024004 page 347, paragraph 3 – page 348, paragraph 1 page 348, paragraph 3; table 2 page 300, paragraph 4 abstract 4							
	ZVENG, ZVDXVIQ, et al.: "Solid-State Slocomyrescen of Finencias from Cambrary Persons and Rived of Leininus existents and Successional "AUDIPANA" of Red RIVEDICAL TURNA. AND FOOD CHEMISTRY VIV. vid. no. 5. Marrit 2000 (2000.03), pages 665-600, XPD0/2267369 abstract, figure 6; table 2 page 696, column 2, paragraph 2 - page 699, column 1, paragraph 4.							
	DAY, A. J., et al.: "Deglycospiction of flavoroid and isoflavorous glycospics by harms small infestive and leve being closoroidate activity: FEBS LETIERS, ELSEVIER SCIENCE PUBLISHERS, AMSTEPDAM, N. vol. 450, n. 0; 25 o September 1998 (1996-09-29), pages 71-75, XPG01268361 ISSN: 0014-5793 abstract, figure 1; table 1 page 74, column 1, paragraph 4.							
	CICEX, MUZAFER et al. "The agicone specificity determining sites are different in 2.4 dhydrony.7 methoxyr.1.4. benzozara-5-noe (IMBADA) glozosalase limite beta -glozosialase) and dhurmase (portplum beta -glozosidase)* JOURNAL OF BIOLOGICAL CIEMBSTRY, vol. 275, no. 26, 30 June 2000 (2000 66: 30), pages 2000 200011, XPRO2267338 shabrate (Iguer 1 page 2000). column 2, paragonal 2- page 20000, advunn 1, paragonal 1.							
	BAK, S. et al. "TRANSCENIC TORACCO AND ARABIDOPES PLANTS EXPRESSING THE TWO MULTIPUNCTIONAL SORRHIM OFFOORDORS PERSON EXPESSING THE TWO AND ACCUMULATE METABOLITES DERIVED FROM INTERMEDIATES IN DUTKERN BIOSYNTHESIS PLANT PHYSIOLOGY, AMERICAN SOCIETY OF PLANT PHYSIOLOGISTS, ROCYNILLE, MU, yo, vil 22, August 2000 (2000-68), pages 1437-1448, XP001006399 ISSN 0032-0899 oiled in the application abstract, (igure 1 page 1440, igure 1440, igure 1440, igure 1440, igure 1440, igure 1440, igure							

# | Application Number | 10561823 | Filing Date | 2005-12-19 | Filing Date |

Examiner Signature		Date Considered				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw lin citation if not in conformance and not considered. Include copy of this form with next communication to applica						

16e Kin Codes of USPTO Patert Documents at www.USPTO.GOV or MPEP 801.04. 2 Enter office that issued the document, by the hov-letter code (WIPO Standard S13.) 3 "For implance patent for comments, the included on the year of the import on many precise the serial runty for patent document, and occurrently the appropriate symbols as indicated on the document under WIPO Standard S1.16 if possible. <sup>9</sup> Applicant is to place a check mark here if English languages translation to statistics.

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number			10561823		
Filing Date			2005-12-19		
First Named Inventor Joerge		Joerg	en Hansen		
	Art Unit		1632		
Examiner Name Attorney Docket Number					
		ec	14455 880US01		

### CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Sea 37 CFF 1.37(e)(1).

### OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 175(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 177(c).

See attached certification statement.

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/peterbscull/	Date (YYYY-MM-DD)	2007-01-12
Name/Print	Peter B. Scuill	Registration Number	37 932

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) and application. Confidentiality is governed by \$5 U.S. C. 12.04 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case: Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Pleater and Trademark Office, U.S. operatment of Commence, P.O. 8bs 1449, Alexandrin, V.S. 2311-1450, D.O. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 8bs 1459, Alexandria, V.S. 2311-1450.

## Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
  application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
  disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
  which became abandoned or in which the proceedings were terminated and which application is referenced by either a
  published application, an application open to public inspections or as issued patent.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.